Sithandiwe Mamutse, APRN
Psychiatric/Mental Health · Crestview Hills, KYNPI 1942820444
Payments from drug & device makers
Across 627 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$973
- Lundbeck LLC$823
- plus $4K from 18 others
What the payments were for
- Food & beverage$13,19799%
- Education$1151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 96 | $2,935 |
| Teva Pharmaceuticals USA, Inc. | 66 | $1,566 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 85 | $1,524 |
| Otsuka America Pharmaceutical, Inc. | 63 | $1,131 |
| Johnson & Johnson | 35 | $973 |
| Lundbeck LLC | 54 | $823 |
| Axsome Therapeutics, Inc. | 24 | $807 |
| Alkermes, Inc. | 28 | $593 |
| Neurocrine Biosciences, Inc. | 26 | $446 |
| Takeda Pharmaceuticals U.S.A., Inc. | 27 | $427 |
| Corium, LLC | 15 | $340 |
| Sunovion Pharmaceuticals Inc. | 20 | $329 |
| Supernus Pharmaceuticals, Inc. | 27 | $318 |
| Noven Therapeutics, LLC | 19 | $258 |
| Vanda Pharmaceuticals Inc. | 8 | $181 |
| Almatica Pharma LLC | 7 | $163 |
| Ironshore Pharmaceuticals Inc. | 7 | $107 |
| Tris Pharma Inc | 7 | $105 |
| Idorsia Pharmaceuticals US Inc | 2 | $103 |
| Bausch Health US, LLC | 4 | $70 |
| Avanir Pharmaceuticals, Inc. | 3 | $62 |
| Alfasigma USA, Inc. | 2 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$1,184
- Austedo XR$490
- Auvelity$436
- CAPLYTA$355
- REXULTI$354
- INVEGA SUSTENNA$247
- AUSTEDO$233
- SPRAVATO$150
- INVEGA TRINZA$121
How this compares
$13,312 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 32 | $268,289 |
| VraylarCariprazine Hcl | 53 | $90,185 |
| AustedoDeutetrabenazine | 11 | $80,535 |
| Invega SustennaPaliperidone Palmitate | 11 | $12,081 |
| TrintellixVortioxetine Hydrobromide | 20 | $10,490 |
| Duloxetine Hcl | 78 | $6,676 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 47 | $3,425 |
| Aripiprazole | 27 | $3,081 |
| Trazodone Hcl | 107 | $1,725 |
| Vilazodone Hcl | 17 | $1,621 |
| Bupropion XlBupropion Hcl | 42 | $1,122 |
| Buspirone Hcl | 104 | $1,121 |
| Risperidone | 75 | $903 |
| Mirtazapine | 38 | $640 |
| Amitriptyline Hcl | 22 | $566 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $446 | $268,28932 claims |
| AbbVieVraylar | $2,935 | $90,18553 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,566 | $80,53511 claims |
| Johnson & JohnsonInvega Sustenna | $973 | $12,08111 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $427 | $10,49020 claims |
| Almatica Pharma LLCSertraline Hcl | $163 | $39445 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Crestview Hills
- Jennifer SampangCrestview Hills$322K
- Molly LutzCrestview Hills$71K
- Brent PlummerCrestview Hills$10K
- Amerika HullCrestview Hills$8K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.